Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study

C. Gudiel, X. Durá-Miralles, J. Aguilar-Company, P. Hernández-Jiménez, M. Martínez-Cutillas, F. Fernández-Avilés, M. Machado, L. Vázquez, P. Martín-Dávila, N. de Castro, E. Abdala, L. Sorli, T.M. Andermann, I. Márquez-Gómez, H. Morales, F. Gabilán, C.M. Ayaz, B. Kayaaslan, M. Aguilar-Guisado, F. Herrera, C. Royo-Cebrecos, M. Peghin, C. González-Rico, J. Goikoetxea, C. Salgueira, A. Silva-Pinto, B. Gutiérrez-Gutiérrez, S. Cuellar, G. Haidar, C. Maluquer, M. Marin, N. Pallarès, J. Carratalá

*Department of Infectious Diseases, Biostatistics Unit, Bellvitge University Hospital, Bellvitge Institute for Biomedical Research (IDIBELL), University of Barcelona, Barcelona, Spain
†Department of Medical Oncology and Department of Infectious Diseases, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
‡Department of Infectious Diseases Unit, 12 de Octubre University Hospital, Madrid, Spain
§Medical Oncology Department, Puerta de Hierro University Hospital, Madrid, Spain
¶Bone Marrow Transplantation Unit, Department of Haematology, Hospital Clinic of Barcelona, Spain
‖Clinical Microbiology and Infectious Diseases Department. Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
¶¶Hematology Department, Salamanca University Hospital, Spain
||Infectious Diseases Department, Ramony Cajal University Hospital, Madrid, Spain
]|Infectious Diseases Department, St.-Louis Hospital, University of Paris, France
\|Facultad de Medicina da Universidade de Sao Paulo, Instituto do Cancer do Estado de Sao Paulo, Brazil
*|Infectious Diseases Service, Hospital del Mar. Infectious Pathology and Antimicrobials Research Group (IPMAR), CEXS-Universitat Pompeu Fabra, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain
**Department of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
***Regional Málaga University Hospital, Málaga, Spain
****Hospital Erasto Gaertner, Curitiba, Brazil
*****Infectious Diseases Department, Reina Sofia University Hospital, Córdoba, Spain
******Hacettepe University Hospital, Ankara, Turkey
*******Infectious Disease and Clinical Microbiology, Ankara City Hospital, Ankara Yildirim Beyazit University, Turkey
********Infectious Diseases Department, Virgen del Rocío University Hospital, Seville, Spain
*********Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina
**********Nostra Senyora de Meritxell Hospital, Andorra
***********Infectious Diseases Department, Santa Maria Misericordia, Udine, Italy

* COVACAN study group: Albassar-Puig A, Bergas A, Maristany M, Antonio M, Laporte-Amargos J, Domingo-Domenech E and Molina K, Bellvitge University Hospital and Institut Català d’Oncologia, IDIBELL, University of Barcelona, Spain. Ruiz-Camps J and Gabira A, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Aguado JM, 12 de Octubre University Hospital, Madrid, Spain. Fernández-Cruz A and Prieto-Martínez P, Puerta de Hierro University Hospital, Madrid, Spain. Marcos-Maeso MA, Cruz-Sequeiros C, Oliver-Calde C, Martinez-Roca A, Hospital Clinic of Barcelona. Institut of Global Health (ISGlobal) and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Kwon M and Baillien R, Gregorio Marañón General University Hospital, Madrid, Spain. Fortín J, Infectious Diseases Department, Ramón y Cajal University Hospital, Madrid, Spain. Tatío M and Molina JM, Infectious Diseases Department, St.-Louis Hospital, University of Paris. Gonçalves réscav Magui AS and Rekko de Luca Ita R, Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, Brazil. Montero MM and Gómez-Junyent J, Hospital del Mar. Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), CEXS-Universitat Pompeu Fabra, Barcelona, Spain. Van Duin D and Merenbloom C, University of North Carolina at Chapel Hill, Department of Medicine, Division of Infectious Diseases, Chapel Hill, North Carolina, USA. Akova M and Duran ZC, Hacettepe University Hospital, Ankara, Turkey. Akca N, Ankara Yildirim Beyazit University, Ankara City Hospital, Turkey. Castaldo N and Tascini C, Santa Maria Misericordia, Udine, Italy. Farillas MC and Bermúdez A, Marqués de Valdecilla University Hospital, Santander, Cantabria, Spain. Bereciartua E, Cruces University Hospital, Bilbao, Spain. Altelas J and Fernandez M, Sanatorio Anchorena, Buenos Aires, Argentina. Santos L, Centro Hospitalario Universitario de São João, Porto, Portugal. Moreno-Mellado E, Virgen de Macarena University Hospital, Instituto de Biomedicina de Sevilla; University of Seville, Spain. Malacalza J and Naretí JP, Bone Marrow Transplant Unit, Hospital Rossi, La Plata, Argentina. Hughes K, Division of Infectious Diseases, University of Pittsburgh and UPMC, Pittsburgh, USA. Tebe C, Biostatistics Unit, IDIBELL, Barcelona, Spain.

† Corresponding author at: Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Institute for Biomedical Research (IDIBELL), University of Barcelona, Barcelona, Spain.
† E-mail address: cgudiel@iconologia.net (C. Gudiel).

1 These authors contributed equally to this work.

https://doi.org/10.1016/j.jinf.2021.07.014
0163-4453/© 2021 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Introduction

Bacterial and fungal infections represent a significant complication in some viral diseases, such as influenza. Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, several studies have been published describing the epidemiology of infectious complications of COVID-19. Co-infections, diagnosed around the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, appear to be uncommon occurring in 0.6 to 3.2% of patients. Bacterial respiratory co-infections with Streptococcus pneumoniae or Staphylococcus aureus are the most common causes of coinfections, whereas respiratory viral co-infections appear to be relatively rare.4,6

In contrast, nosocomial superinfections appear to be more frequent than co-infections, particularly among patients admitted to the intensive care unit (ICU) and those receiving high doses of corticosteroids. These patients develop high rates of bloodstream infections and ventilator-associated pneumonia. Additionally, emerging data have demonstrated unexpectedly high rates of fungal infections, such as candidemia and invasive aspergillosis, particularly among mechanically ventilated patients. Infections due to multidrug-resistant (MDR) organisms have been reported some series. Importantly, outcomes of patients with superinfections are likely to be poor, with prolonged hospital stay and higher mortality.4,6

Onco-hematological patients, including hematopoietic stem cell transplant (HSCT) recipients are at a higher risk of acquiring COVID-19, with the associated mortality reported to be higher than that in the general population. Yet, there is scarce information regarding infectious complications in cancer patients with COVID-19. Cancer as a comorbidity has been reported to be higher in patients with superinfections than in those without these complications. However, there are only two studies that mention very briefly the incidence and types of infectious complications. In a series of 536 patients with hematologic malignancies, of whom 82 were allologeneic HSCT recipients, the only information provided was that 187 patients (34.8%) presented additional infections. In another series involving 77 HSCT recipients (37 allogeneic, 37 autologous, and five CAR T-cell recipients), ten patients developed infections (13%), caused by multiple organisms in some patients. The infections reported were bloodstream infections (BSIs) (n = 3), fungal pneumonia (n = 3), urinary tract infections (UTIs) (n = 2), Clostridioides difficile colitis (n = 2), bacterial pneumonia (n = 1) and Epstein-Barr virus reactivation (n = 1). Given these knowledge gaps, we designed an international multicenter cohort study of onco patients with COVID-19. Our objectives were to define the epidemiology, risk factors and outcomes of infectious complications in these individuals, with a focus on co-infections present at the time of COVID-19 diagnosis and superinfections developing within 48 h of admission.

Methods

Study design and patients

The COVICAN registry was an international, multicenter, combined prospective/retrospective, observational cohort study of adult patients with cancer and COVID-19, across 28 hospitals from 9 countries in Europe, North America and South America from 1 March 2020 to 30 June 2020 (COVICAN registry). A list of the participating centers is provided in the Supplementary Material. All
patients had an active malignancy or were HSCT recipients with COVID-19, defined as symptoms of COVID-19 with a positive real-time reverse transcription PCR (RT-PCR) nasopharyngeal or oropharyngeal swab test. Active cancer was defined as metastatic cancer or anticancer treatment in any setting (curative, radical, adjuvant, or neoadjuvant) or administration of with cytotoxic chemotherapy or radiotherapy within the past 6 months. The COVICAN registry was built and maintained as an electronic REDCap database housed at Bellvitge University Hospital. Data collection was either retrospective or prospective. All patients were included in the analysis of co-infections at diagnosis, while only patients admitted for at least 48 h were included in the analysis of superinfections that developed during hospitalization. The study was approved by the Institutional Review Board of Bellvitge University Hospital (reference number PR133/20) and by the research ethics committees of the participating centers. Furthermore, it was conducted according to the guidelines of the Declaration of Helsinki. The need for informed consent was waived for retrospective cases by the clinical research ethics committees.

### Data collection and procedures

We collected data on demographics, comorbidities, cancer status and therapy, laboratory tests, microbiological results (cultures and non-culture diagnostics such as fungal biomarkers and viral PCR results), treatment, and outcomes. All testing and treatment was conducted as routine care by the individual centers.

### Definitions

Co-infections or nosocomial superinfections were defined as infections occurring at COVID-19 diagnosis or after 48 h of hospital admission for COVID-19, respectively. Neutropenia was defined as an absolute neutrophil count < 500 per mm$^3$.

Infectious were defined using the Centers for Disease Control National Healthcare and Safety Network. A bloodstream infection (BSI) was defined as the growth of bacteria or fungi in at least one blood culture. BSIs caused by skin colonizers such as coagulase-negative staphylococci (CoNS) were considered to be significant.
when the pathogens grew in two or more blood cultures drawn from different sites. Catheter-related BSIs were diagnosed in patients using at least one of the following criteria: (1) positive peripherally drawn blood cultures and positive blood cultures drawn from any of the catheter lumens; (2) time to positivity of at least 120 min for catheter-drawn blood cultures; or (3) positive culture of the same microorganism as that isolated from the catheter tip. Episodes of polymicrobial BSIs were those in which more than one type of organism was isolated from one or more blood cultures within a 72 h period. Bacterial respiratory infections were diagnosed in patients with one or more positive cultures of respiratory pathogens obtained from the blood, pleural fluids, sputum, bronchoalveolar lavage, and tracheal aspirate and/or a positive urinary S. pneumoniae antigen test. Other respiratory pathogens such as influenza A and B viruses, respiratory syncytial virus, parainfluenza virus and metapneumovirus were also studied in respiratory samples, based on the requests of the attending physician. Respiratory infections without microbiological diagnosis were considered in patients with the following criteria: (1) fever; (2) respiratory symptoms; (3) new pulmonary infiltrates; (4) exclusion of other non-infectious causes of pulmonary infiltrates. A urinary infection was defined as the growth of bacteria or fungi in a cultured urine sample from a patient with clinical symptoms and/or when a urinary infection was considered to be clinically significant by the researchers. 

Aspergillus spp. tracheobronchitis was indicated by the isolation of Aspergillus species from respiratory samples of patients with purulent secretions and no radiological images. Invasive aspergillosis was diagnosed as possible, probable or proven according to EORTC/MSGERC criteria. 17

Statistical analysis

Descriptive statistics were used to determine characteristics of patients and infections. To compare the characteristics, risk factors and outcomes between infected and non-infected patients, the Mann-Whitney U Fisher test, chi-square and Fisher exact tests were used for categorical and continuous variables, as appropriate. Patients with and without co-infections were compared in a univariate analysis in order to identify potential risk factors for co-infection at COVID-19 diagnosis. Similarly, patients with and without superinfections were compared in a univariate analysis in order to identify potential risk factors for superinfections during hospitalization. Multivariate logistic regression analyses were performed to identify independent risk factors for co-infections and superinfections, using variables that achieved statistical significance in the univariate analysis. P-values < 0.05 were considered significant.

Results

A total of 684 patients were included, all of whom had data available about co-infections with COVID-19; 590 of these patients also had follow-up data for nosocomial superinfections. Three hundred patients had an underlying hematological malignancy: lymphoma (32.6%, 98/300) and multiple myeloma (20.6%, 62/300) were the most common conditions (Table 1). Among the 384 patients with solid tumors, lung (22.1%, 85/384) and breast cancer (16.9%, 62/384) were the most frequent malignancies (Table 1).

Co-infections at COVID-19 diagnosis

Overall, 7.8% (54/684) of patients presented with co-infections. The characteristics of patients with and without co-infections are shown in Table 1. There were no relevant differences in the baseline characteristics of the patients. However, higher levels of C-reactive protein (CRP) and the presence of neutropenia at diagnosis were more frequently reported in patients with co-infections. Antibiotic therapy was more frequently administered in this group of patients, particularly carbapenems (37.8% vs 19%, p = 0.006) and piperacillin-tazobactam (37.8% vs 23.1%, p=0.044). Patients with co-infections were more likely to present worse outcomes, with higher rates of acute respiratory distress syndrome (56.9% vs 30.7%, p < 0.001) and a higher overall in-hospital case-fatality rate (53.8% vs 30.6%, p = 0.001).

Table 2 details the types and etiologies of the 54 co-infections identified at COVID-19 diagnosis. All co-infections were bacterial. Respiratory tract infections were the most common (38.8%), followed by BSIs (33.3%). Streptococcus pneumoniae and Gram-negative bacilli (which included three cases of Pseudomonas aeruginosa) were the most common causes of respiratory tract infections (42.8% (9/21) and 33.3% (7/21), respectively). Eighty nine percent of S. pneumoniae pneumonias were diagnosed by urinary antigen test. Three episodes were associated with BSI (Haemophilus influenzae (n = 2) and Escherichia coli (n = 1)), and two episodes were polymicrobial. Among BSI episodes, catheter-related BSIs due to CoNS were the most common cause (33.3%, 6/18), followed by

| Table 2 | Type and microbiological etiology of 54 co-infections occurring in 54 cancer patients at COVID-19 diagnosis. |
| --- | --- |
| Co-infections at COVID-19 diagnosis | N (54/684 (7.8%)) |
| Respiratory tract infections<sup>a</sup> | 21 (38.8%) |
| Streptococcus pneumoniae<sup>b</sup> | 9 |
| Moraxella catarrhalis | 3 |
| Haemophilus influenzae<sup>c</sup> | 3 |
| Pseudomonas aeruginosa | 3 |
| E. coli<sup>d</sup> | 1 |
| Klebsiella pneumoniae | 1 |
| Enterobacter cloacae | 1 |
| Serratia marcescens | 1 |
| Staphylococcus aureus<sup>e</sup> | 1 |
| Bacteremia<sup>f</sup> | 18 (33.3%) |
| E. coli<sup>g</sup> | 5 |
| Viridans group streptococci | 3 |
| Enterococcus faecium | 2 |
| P. aeruginosa | 1 |
| Listeria monocytogenes | 1 |
| Capnocytophaga spautigena | 1 |
| S. aureus | 1 |
| Catheter-related bacteremia | 6 |
| Coagulase-negative staphylococci | 6 |
| Micrococcus letis | 1 |
| Urinary tract infection<sup>h</sup> | 15 (27.7%) |
| E. coli<sup>i</sup> | 9 |
| K. pneumoniae | 2 |
| Enterococcus faecalis | 2 |
| Klebsiella oxytoca | 1 |
| Proteus mirabilis | 1 |
| P. aeruginosa | 1 |
| Enterobacter aerogenes | 1 |
| Enterococcus faecium | 1 |

<sup>a</sup> Two episodes were polymicrobial: E. coli + Streptococcus pneumoniae (n = 1), and Serratia marcescens + Enterobacter cloacae (n = 1).

<sup>b</sup> Eight episodes were diagnosed by the pneumococcal urinary antigen test.

<sup>c</sup> Two episodes were diagnosed by positive blood cultures.

<sup>d</sup> This episode was associated with bacteremia.

<sup>e</sup> Positive culture from pleural effusion.

<sup>f</sup> Three episodes were polymicrobial: E. coli + viridans group streptococci (n = 1), E. coli + Enterococcus faecium (n = 1), and Pseudomonas aeruginosa + Staphylococcus aureus (n = 1).

<sup>g</sup> Three episodes were polymicrobial: Klebsiella oxytoca + E. faecium (n = 1), E. coli + E. faecalis (n = 1), and P. aeruginosa + Proteus mirabilis (n = 1).

<sup>h</sup> One episode was associated with bacteremia.

C. Gudiol, X. Durà-Miralles, J. Aguilar-Company et al. 
Journal of Infection 83 (2021) 306–313

309
E. coli (27.7%, 5/18) and viridans group streptococci (VGS) (16.6%, 3/18). Three episodes of BSI were polymicrobial. Among the UTIs, E. coli was the most common pathogen (60%), and three episodes were polymicrobial.

The risk factors for co-infections at COVID-19 diagnosis are also shown in Table 1. By univariate analysis, higher levels of CRP and the presence of neutropenia at COVID-19 diagnosis were more frequently seen in patients with co-infections. In multivariate logistic regression, neutropenia was found to be the only significant independent risk factor for co-infections at COVID-19 diagnosis.

Superinfections during hospitalization

Overall, 82 patients developed 113 superinfections during hospitalization (19.1%). Table 3 outlines the characteristics, outcomes and risk factors of patients with and without superinfections during hospitalization. Patients with hematologic malignancies, particularly those with lymphoma, were more likely to develop superinfections than those with solid tumors (57.3% vs. 42.7%, p = 0.023). Patients treated with immunotherapy or targeted therapies in the previous 3 months were less likely to present superinfections than those were not (11% vs. 22.4%, p = 0.018). In contrast, neutropenia (10.8% vs. 4.2%, p = 0.04), and the use of corticosteroids for the treatment of COVID-19 (48.1% vs. 36.9%, P = 0.049), were significantly more common in patients presenting with superinfections. In multivariate analysis, only neutropenia and ICU admission were found to be independent risk factors for developing a superinfection during hospitalization. Antibiotic and antifungal therapies were more frequently administered in this group of patients, particularly carbapenems (44.3% vs. 16.2%, p < 0.001) and piperacillin-tazobactam (36.7% vs. 22.2%, p = 0.010). Patients with superinfections had poorer outcome than those without superinfections, with higher rates of acute respiratory distress syndrome (44.3% vs. 31.3%, p = 0.028), ICU admission (35% vs. 10.1%, p < 0.001), and invasive mechanical ventilation (33.8% vs. 5.9%, p < 0.001), as well as higher ICU-associated case-fatality rates (14.1% vs 4.7%, p = 0.003).

The types and etiologies of the 113 episodes of superinfections occurring in 82 cancer patients are detailed in Table 4. Respiratory tract infections were the most frequent infectious complications (46/113, 40.7%). In 17 cases (36.9%), no microorganisms were identified. Gram-negative bacteria accounted for more than half of the cases (52.1%), with P. aeruginosa being the most common (34.7%). Aspergillus fumigatus was the etiological agent in three cases of tracheobronchitis (one polymicrobial with P. aeruginosa). Only seven cases of opportunistic infections developed, including five cases of cytomegalovirus viremia, one case of probable invasive pulmonary aspergillosis (IPA) and one case of BK polyomavirus-associated hemorrhagic cystitis. Only six infections were caused by MDR organisms: three due to MDR P. aeruginosa, two due to methicillin-resistant S. aureus and one caused by extended-spectrum β-lactamase-producing Enterobacter spp.

Discussion

In our large multinational cohort of onco-hematological patients with COVID-19, we found that the rate of co-infections at the time of diagnosis was more than double the rate reported in the general population, but the rate of superinfections was comparable to those observed in previous reports in the general population. Neutropenia was a major risk factor for both co-infections and superinfections, whereas ICU admission was also a risk factor for superinfections. Surprisingly, no respiratory viral co-infections were encountered, and the rate of opportunistic infections, particularly IPA, was unexpectedly low. Nevertheless, patients with co-infections and/or superinfections presented worse outcomes, with higher case fatality rates. Taken together, our data highlight the need for improved diagnostics to identify patients at highest risk for infections following COVID-19, in order to prioritize these patients for antimicrobial therapy.

Although there are some published studies involving large cohorts of onco-hematological patients with COVID-19, data on the rates, characteristics and outcomes of infectious complications in this population are lacking. This is of special concern since cancer patients are at a higher risk of acquiring COVID-19. Due to their often severely impaired immune system, it has been widely assumed that the risk of developing additional infectious complications is high. As a consequence, it has been reported that the number of antimicrobial prescriptions in cancer patients with COVID-19 has been high, even in patients showing no evidence of infectious complications during hospitalization, which reached 81.5% in our study. This is of special concern in the current era of emerging antimicrobial resistance, since a reduction of antibiotic consumption is a cornerstone in the fight against the development of resistance.

In our series, co-infections mainly occurred in patients with neutropenia and high levels of CRP. These included both bacterial co-infections commonly encountered in cancer patients (S. pneumoniae, P. aeruginosa), as well as BSIs, which are common in cancer patients due to the presence of indwelling catheters, mucositis, and neutropenia. These findings suggest that antibiotics may not need to be administered to all cancer patients who present with COVID-19, but may instead be targeted more to those with neutropenia and elevated CRP levels. No other respiratory viruses were identified, although this may have been a result of limited diagnostic testing in 2020, due to swab and PCR reagent shortages.

Nearly 20% of patients developed nosocomial superinfections, which was lower than we had originally expected, as many patients had previously received immunosuppressive therapies and/or immunomodulatory treatments for COVID-19. This finding may be a result of limitations in diagnostic testing in patients who are under COVID-19 transmission-based precautions. ICU stay and neutropenia were risk factors for superinfections, further suggesting that even among hospitalized patients, empiric antibiotics may potentially be withheld for most individuals, except for critically ill patients and those with neutropenia. Additional studies are needed to help optimize antibiotic use in critically ill neutropenic cancer patients, in whom distinguishing between respiratory failure and fever from COVID-19 versus an underlying bacterial infection can be difficult.

Interestingly, opportunistic infections were unexpectedly rare, with only one case of documented IPA, although three patients were diagnosed with Aspergillus tracheobronchitis. The rates of COVID-19-associated pulmonary aspergillosis (CAPA) reported in the literature vary greatly, ranging from 0.1% to 47.4%. We hypothesize that these findings may be explained by the challenges encountered in diagnosing CAPA: diagnostic criteria are poorly-defined, the radiological findings are often non-specific in individuals with concurrent COVID-19 pneumonia, testing may be frequently sent due to lack of clinician awareness, the performance of fungal biomarkers assays in CAPA is unknown (although the galactomannan assay is expected to have a good performance in neutropenia), and it is difficult to distinguish colonization from infection. Nonetheless, the rate of IPA observed in patients with COVID-19, even when they carry a baseline immunosuppressive condition (such as our patients), appears to be much lower than that observed in patients with influenza. Other invasive fungal infections, such as Candida, were not observed in our cohort compared to other reports.

The in-hospital case-fatality rate in our cohort was 32.4% (215/664), which is significantly higher than that reported for the general population, but in line with several other reports involving cancer patients. Patients with infectious complications in

C. Gudiol, X. Durá-Miralles, J. Aguilar-Company et al. Journal of Infection 83 (2021) 306–313
our study had worse outcomes, higher rates of acute respiratory distress syndrome, ICU admission, and increased mortality. These findings are consistent with those of previous reports of oncology patients with respiratory viral infections.\(^5\)\(^6\)\(^7\)\(^9\) However, there are several variables that may influence the outcomes of cancer patients with COVID-19, particularly the presence of uncontrolled underlying malignancy. Thus, these worse outcomes cannot be entirely attributed to the development of infectious complications.

Limitations of the study include its partial retrospective design and the fact that diagnostic testing was performed according to the discretion of the individual sites. Our rate of infection may be falsely low, particularly in the setting of enhance COVID-19 transmission-based precautions limiting the ability of clinicians to perform diagnostic tests for infection. Additionally, systematic testing for viral co-infections was not performed by all participating centers. Despite these limitations, ours is the first published report addressing infectious complications in immunocompromised cancer patients with COVID-19. We include data for a large number of patients from 28 centers located in nine countries around the world, thereby improving the generalizability of our results.

In conclusion, in our large multinational cohort of cancer patients with COVID-19, co-infections were higher than in the gen-

### Table 3
Main characteristics of 82 patients with superinfections after 48 h of hospitalization for COVID-19.

| Characteristic                           | Patients without a superinfection | Patients with a superinfection | Adjusted\(^a\) OR (95%) CI | P value |
|-----------------------------------------|-----------------------------------|--------------------------------|--------------------------|--------|
| Age, years (median, IQR)               | 67 (40–84)                        | 47 (22–72)                     | 0.084                    | 0.98 (0.95–1.00) | 0.011 |
| Male sex                               | 278 (54.7)                        | 55 (67.1)                      | 0.041                    | 0.93 (0.45–1.92) | 0.85 |
| Hematological malignancy               | 219 (43.1)                        | 47 (57.3)                      | 0.023                    | 1.07 (0.49–2.31) | 0.85 |
| Lymphoma                               | 66 (13)                           | 19 (23.2)                      |                          |        |
| Acute leukemia                          | 29 (5.7)                          | 9 (11)                         |                          |        |
| Multiple myeloma                        | 52 (10.2)                         | 6 (7.3)                        |                          |        |
| Myelodysplastic syndrome                | 15 (3)                            | 1 (1.2)                        |                          |        |
| Chronic lymphocytic leukemia            | 40 (7.9)                          | 7 (8.5)                        |                          |        |
| Hematopoietic stem cell transplant      | 44 (20.1)                         | 6 (12.8)                       |                          |        |
| Solid tumor                             | 289 (57)                          | 35 (42.7)                      | 0.023                    |        |
| Lung cancer                             | 56 (19.4)                         | 7 (20)                         |                          |        |
| Breast cancer                           | 60 (20.8)                         | 0                              |                          |        |
| Colorectal cancer                       | 53 (18.4)                         | 4 (11.4)                       |                          |        |
| Prostate cancer                         | 227 (76)                          | 6 (17.1)                       |                          |        |
| Upper GI tract cancer                   | 19 (6.6)                          | 1 (2.9)                        |                          |        |
| Urinary tract cancer                    | 16 (5.6)                          | 3 (8.6)                        |                          |        |
| Gynecological cancer                    | 13 (4.5)                          | 5 (16.7)                       |                          |        |
| Head and neck cancer                    | 9 (3.1)                           | 4 (11.4)                       |                          |        |
| Hepatobiliary tumor                     | 15 (5.1)                          | 5 (14.3)                       |                          |        |
| Other                                   | 15 (5.1)                          | 0                              |                          |        |
| Comorbidities                           |                                   |                                |                          |        |
| Hypertension                            | 241 (47.5)                        | 39 (47.6)                      | 1.00                     |        |
| Diabetes mellitus                       | 99 (19.6)                         | 15 (18.3)                      | 0.88                     |        |
| COPD                                    | 37 (57.8)                         | 10 (55.6)                      | 1.00                     |        |
| Chronic heart disease                   | 19 (3.7)                          | 4 (4.9)                        | 0.54                     |        |
| Chronic renal disease                   | 14 (2.8)                          | 4 (4.9)                        | 0.30                     |        |
| Immunosuppressive therapy              |                                   |                                |                          |        |
| Previous corticosteroids (1 m)          | 130 (25.7)                        | 23 (28)                        | 0.68                     |        |
| Prednisone > 10 mg/day                  | 75 (58.6)                         | 13 (59.1)                      | 1.00                     |        |
| Immune therapy/targeted therapies      | 114 (22.4)                        | 9 (11)                         | 0.018                    | 0.50 (0.17–1.43) | 0.20 |
| Monoclonal antibodies                   | 29 (5.7)                          | 7 (8.5)                        | 0.32                     |        |
| Neutropenia (< 500 cells/mm\(^3\))     | 20 (42)                           | 8 (10.8)                       | 0.040                    | 4.88 (1.35–17.5) | 0.015 |
| Inflammatory biomarkers (median, IQR)   |                                   |                                |                          |        |
| C-reactive protein (mg/L)               | 65 (12–250)                       | 79.4 (13–381)                  | 0.16                     | 1.00 (1.00–1.00) | 0.12 |
| Procalcitonin (μg/L)                    | 0.10 (0.02–3.94)                  | 0.24 (0.11–2.00)               | 0.94                     |        |
| Ferritin (μg/L)                         | 1.247 (30–12,474)                 | 654 (466–11,330)               | -0.001                   |        |
| Creatine kinase (U/L)                   | 66 (16–296)                       | 85 (16–185)                    | 0.54                     |        |
| Therapy                                 |                                   |                                |                          |        |
| Hydroxychloroquine                      | 375 (92.4)                        | 60 (83.3)                      | 0.023                    |        |
| Lopinavir/ritonavir                     | 222 (54.7)                        | 44 (61.1)                      | 0.36                     |        |
| Remdesivir                              | 15 (3.7)                          | 6 (8.2)                        | 0.11                     |        |
| Tocilizumab                             | 75 (18.5)                         | 18 (25)                        | 0.20                     |        |
| Corticosteroids                         | 185 (36.4)                        | 39 (48.1)                      | 0.049                    | 2.03 (0.96–4.30) | 0.062 |
| Corticosteroids and/or immunomodulators | 204 (40.2)                       | 42 (51.9)                      | 0.053                    |        |
| Antibacterial therapy                   | 414 (81.5)                        | 79 (97.5)                      | -0.001                   |        |
| Aminocillin-clavulanate                 | 52 (12.6)                         | 9 (11.4)                       | 0.85                     |        |
| Broad-spectrum cephalosporins           | 51 (12.3)                         | 16 (20.3)                      | 0.059                    |        |
| Carbapenems                             | 67 (16.2)                         | 35 (44.3)                      | -0.001                   |        |
| Quinolones                              | 25 (6)                            | 8 (10.1)                       | 0.21                     |        |
| Piperacillin-tazobactam                 | 92 (22.2)                         | 29 (36.7)                      | 0.010                    |        |
| Antifungal therapy                      | 9 (1.8)                           | 5 (6.2)                        | 0.032                    |        |
| Acute respiratory distress syndrome     | 158 (31.3)                        | 35 (44.3)                      | 0.028                    |        |
| ICU admission                           | 51 (10.1)                         | 28 (35)                        | -0.001                   | 4.98 (2.26–10.9) | <0.001 |
| Invasive mechanical ventilation         | 30 (5.9)                          | 27 (33.8)                      | -0.001                   |        |
| Overall in-hospital case-fatality rate  | 157 (31.3)                        | 26 (32.5)                      | 0.89                     |        |
| ICU-associated case-fatality rate       | 23 (4.7)                          | 11 (14.1)                      | 0.003                    |        |

\(^{5}\) ICU, intensive care unit. \(^{6}\) COPD, Chronic obstructive pulmonary disease. \(^{7}\) Broad-spectrum cephalosporins: cefepime, ceftazidime, cefotaxime-tazobactam and ceftazidime-avibactam. \(^{8}\) Antifungal therapy (more than one antifungal was administered in some patients): fluconazole \((n = 5)\), voriconazole \((n = 3)\), micafungin \((n = 3)\), caspofungin \((n = 2)\), anidulafungin \((n = 2)\) posaconazole \((n = 1)\), Amphotericin B \((n = 1)\).
eral population, mainly affected neutropenic patients and critically ill ICU patients, and were associated with severe disease and poor outcomes. Further studies are needed to define the risk factors for bacterial and fungal infections in oncology patients with COVID-19 to better optimize antimicrobial use in these vulnerable individuals, and avoid unnecessary antibiotic exposure.

| Table 4 | Detailed microbiological etiology of 113 superinfections occurring in 82 cancer patients after 48 of hospitalization for COVID-19. |
|----------|--------------------------------------------------------------------------------------------------|
|          | Superinfections during hospitalization for COVID-19 | 113/590 (19.1%) |
| Ventilator-associated pneumonia | Pseudomonas aeruginosa | 10 (8.8%) |
| | Enterobacter aerogenes + Burkholderia cepacia | 5 |
| | Not identified | 4 |
| Non-ventilator-associated pneumonia | Pseudomonas aeruginosa | 18 (15.9%) |
| | Enterobacter aerogenes | 3 |
| | Staphylococcus aureus | 2 |
| | E. coli | 1 |
| | Stenotrophomonas maltophilia | 1 |
| | Not identified | 11 |
| Nosocomial tracheobronchitis | P. aeruginosa | 18 (15.9%) |
| | Aspergillus fumigatus | 9 |
| | Staphylococcus aureus | 3 |
| | Enterobacter aerogenes | 2 |
| | E. coli | 1 |
| | S. maltophilia | 1 |
| | Acinetobacter baumannii | 1 |
| | Not identified | 2 |
| Bacteremia | E. coli | 31 (27.4%) |
| | P. aeruginosa | 4 |
| | Enterococcus faecalis | 3 |
| | Enterococcus faecium | 2 |
| | Candida albicans | 1 |
| | Candida parapsilosis | 1 |
| Urinary tract infection | E. faecalis | 17 (12.7%) |
| | E. faecalis | 3 |
| | E. coli | 3 |
| | P. aeruginosa | 3 |
| | Proteus mirabilis | 2 |
| | Staphylococcus aureus | 1 |
| | Citrobacter koseri | 1 |
| | Candida krusei | 1 |
| | Candida glabrata | 1 |
| | Candida parapsilosis | 1 |
| Clostridium difficile coliitis | 6 (5.3%) |
| Other bacterial infections | Biliary tract infections | 4 (3.5%) |
| | Peritonitis | 3 |
| Opportunistic infections | Invasive pulmonary aspergillosis | 7 (6.1%) |
| | Cytoxanomalvgovirus viremia | 5 |
| | BK polyomavirus-associated hemorrhagic cystitis | 1 |

---

### Declaration of Competing Interest

The authors declare no conflicts of interest.

### Acknowledgments

We thank the ESCMID Study Group for Immunocompromised Hosts (ESGICH) for supporting the study. We also thank the Centre de Recerca de Catalunya (CERCA) Programme and the Generalitat de Catalunya for institutional support.

### Funding statement

This study was supported by the Spanish Plan Nacional de I+D 2013–2016, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, and the Spanish Network for Research in Infectious Diseases (RIEPID grant: RD16/0016/0001). It was also co-financed by the European Development Regional Fund ‘A Way to Make Europe’, Operational Programme Smart Growth 2014–2020.

### Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jinf.2021.07.014.

### References

1. Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with influenza pandemics. *Front Microbiol* 2017;8:1041.

2. Hughes S, Troise O, Donaldson H, Mughal N, Moore ISP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. *Clin Microbiol Infect* 2020;26:1395–9.

3. Karaba SM, Jones G, Helset T, et al. Prevalence of co-infection at the time of hospital admission in COVID-19 patients, a multicenter study. *Open Forum Infect Dis* 2020;8(1):ofaa578. doi:10.1158/ESGICH.

4. Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. *Clin Microbiol Infect* 2021;27:83–8. doi:10.1016/j.cmi.2020.07.041.

5. Søgaard KK, Baettig V, Osthoff M, et al. Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalised with COVID-19 pneumonia. *J Intensive Care* 2021;9(1):10. doi:10.1186/s40560-021-00526-y.

6. Musuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safter D. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. *Plos One* 2021;16(5):e0251170. doi:10.1371/journal.pone.0251170.

7. Smith L, Karaba SM, Amous J, et al. Hospital-acquired infections among adult patients admitted for coronavirus disease 2019 (COVID-19). *Infect Control Hosp Epidemiol* 2021;13:1–4. doi:10.1017/ice.2021.148.

8. Arenitz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. *JAMA* 2020;323:1612–14. doi:10.1001/jama.2020.4326.

9. Falcone M, Tiseo G, Giordano C, et al. Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. *J Antimicrob Chemother* 2021;76:1078–84. doi:10.1093/jac/dkaa330.

10. Nucci M, Barreiros G, Guimarães LF, Deriquel VEM, Castilhos AC, Noué SA. Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic. *Microbes* 2021;64:152–6. doi:10.1111/mic.13225.

11. Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. *Cancer Discov* 2020;10:783–91. doi:10.1158/2159-8290.CD-20-0516.

12. Mehta V, Goel S, Kabarriri R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. *Cancer Discov* 2020;10:915–41. doi:10.1158/2159-8290.CD-20-0016.

13. Zhang H, Han H, He T, Labbe KE, et al. Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis. *J Natl Cancer Inst* 2021;113:371–80. doi:10.1093/jnci/dja168.

14. Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicenter, cohort study. *Lancet Haematol* 2020;7:e737–45. doi:10.1016/S2352-336X(20)30249-5.

15. Shah GL, DeWolf S, Lee VJ, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. *J Clin Invest* 2020;130:6656–67. doi:10.1172/JCI147777.
16. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control* 2008;36:309–32.

17. Donnelly JP, Chen SC, Kaufman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin Infect Dis* 2020;71:1367–76.

18. Kuderer NM, Cheuerei TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet* 2020;395(10241):1907–18. doi:10.1016/S0140-6736(20)31187-9.

19. Pinato DJ, Zambelli A, Aguilar-Company J, et al. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. *Cancer Discov* 2020;10:1465–74. doi:10.1158/2159-8290.CD-20-0773.

20. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. *Lancet* 2020;395(10241):1919–26. doi:10.1016/S0140-6736(20)31173-9.

21. Robolotti EV, Bahady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. *Nat Med* 2020;26:1218–23. doi:10.1038/s41591-020-0979-0.

22. Raad I, Hachem R, Hanna H, et al. Sources and outcomes of bloodstream infections in cancer patients: the role of central venous catheters. *Eur J Clin Microbiol Infect Dis* 2007;26:549–56.

23. Gudiol C, Bodro M, Simonetti A, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. *Clin Microbiol Infect* 2013;19:474–9.

24. Felkar A, Lampros A, Mayaux J, et al. Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU. *Am J Respir Crit Care Med* 2021;203:307–17. doi:10.1164/rccm.202009-3400OC.

25. Salmanton-Garcia J, Sprute R, Stenler J, et al. FungiScope European Confederation of Medical Mycology/The International Society for Human and Animal Mycology Working Group. COVID-19-Associated Pulmonary Aspergillosis, March-August 2020. *Eur Respir J* 2021;57:600–7. doi:10.1183/13993003.01135-2021.

26. Machado M, Valerio M, Álvarez-Usía A, et al. Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity. *Mycoses* 2021;64:132–43. doi:10.1111/myc.13213.

27. Borman AM, Palmer MD, Fraser M, et al. COVID-19-Associated Invasive Aspergillosis: data from the UK National Mycology Reference Laboratory. *J Clin Microbiol* 2020;58:e02136-20. doi:10.1128/JCM.02136-20.

28. Mitaka H, Kuno T, Takagi H, Patrawalla P. Incidence and mortality of COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis. *Mycoses* 2021 Online ahead of print. doi:10.1111/myc.13292.

29. Agrifoglio A, Cachafeiro I, Figueira JC, Añón JM, García de Lorenzo A. Critically ill patients with COVID-19 and Candidaemia: we must keep this in mind. *J Mycol Med* 2020;30:4:101012.

30. Mastrangelo A, Germinario BN, Ferrante M, et al. Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls. *Clin Infect Dis* 2020 ciaa1594Online ahead of print. doi:10.1093/cid/ciaa1594.